1. Keating MJ, Giscombe L, Tannous T, Reddy N, Mukkamalla SKR, DeSouza A, et al. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer. J Oncol Pharm Pract. 2019;25(8):1927–32.
2. Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017;18(1):132–42.
3. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605.
4. Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018;7:1513.
5. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.